Zantac Use May Increase the Risk of Breast Cancer

Posted on by Edward Lott

Women using Zantac could have a higher chance of developing a type of breast cancer compared to those not using the medication, according to a peer-reviewed study. If your firm represents plaintiffs injured by drugs, female Zantac users who later develop ductal carcinoma are potential clients worth pursuing.

FDA Zantac Recall |

Study looks at Zantac’s active ingredients and their impact on hormone

A peer-reviewed study by the American Association for Cancer Research and the American Society of Preventive Oncology published in 2008 examined the relationship between H2 antihistamine-blockers like Zantac and breast cancer.

Histamine H2-receptor antagonists, also known as H2 blockers, have been used to treat duodenal and gastric ulcers and prevent their return, reports the Mayo Clinic, by limiting the amount of acid produced in the stomach. Over the counter versions were to relieve or prevent heartburn, acid indigestion, and sour stomach.

The Food and Drug Administration asked the manufacturers of Zantac and those making similar medications to stop selling the products in April. Using them can cause Nitrosodimethylamine (NDMA) to be released in the body. That organic compound has been linked to an increased risk of esophageal, oral cavity, and pharynx cancers.

Ranitidine can boost hormone levels and increase the risk of cancer

The study didn’t find a causal link between ranitidine (Zantac’s active ingredient) and breast cancer in general but it did suggest that those regularly using these medications had an increased risk of ductal carcinoma. It found, “current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma…”

Some H2 blockers, especially cimetidine and ranitidine, increase levels of the hormone prolactin. Its role in promoting breast cancer growth isn’t as well-known as estrogen and progesterone, but prolactin’s effect on breast cancer has drawn increasing attention, according to one 2017 study.

See also  Top 7 legal tech stories from the Journal in 2019

Both animal and laboratory data suggest prolactin is involved in the creation of tumors by promoting cell creation, increasing the number of cells changing from one type to another, improving a tumor’s ability to attract blood flow and invade healthy tissue. This relationship between increased prolactin levels and postmenopausal breast cancer risk makes the use of H2 blockers a potential risk factor.

The 2008 study authors combined data from two population-based case-control studies conducted in western Washington. They looked at the possible connection between using H(2) blockers and the risk of developing different types of breast cancers among 1,941 cases and 1,476 control group members 55 to 79 years old.

A study found chances of a type of ductal carcinoma increase with the use of ranitidine

The study found women in this age range using H(2) blockers with ranitidine were 2.4 times more likely to develop estrogen receptor-positive/progesterone receptor-positive ductal carcinoma, compared to others who didn’t use the medication.

The study concluded that H(2) blocker use doesn’t increase the risk of breast cancer in general, but it may increase the risk of hormone-receptor-positive ductal carcinoma. It recommended that further studies should be done to confirm their findings.

ForLawFirmsOnly Marketing can help your law firm grow

How do you compete against other firms for quality, profitable Zantac cases? Hire ForLawFirmsOnly Marketing. Avoid the problems and expensive marketing and advertising. Reach out to potential clients ready, willing, and able to retain your legal services.

We can obtain the highest quality leads so you won’t have to put in the work to do it yourself. We use highly sophisticated, targeted marketing and advertising campaigns to get the results you can’t get on your own.

See also  Sedgwick confirms some staff layoffs after more partner departures

Get started before your competitors do. There is a limit to how many clients we can onboard.

Contact us for a quote. Call 855-943-8736 or use our Request A Quote form.

Edward Lott, Ph.D., M.B.A.
President and Managing Partner
ForLawFirmsOnly Marketing, Inc.
Ed can be reached at (or visit his website)
855-943-8736 ext. 101

Zantac Use May Increase the Risk of Breast Cancer
Article Name
Zantac Use May Increase the Risk of Breast Cancer
Women using Zantac could have a higher chance of developing a type of breast cancer compared to those not using the medication, according to a peer-reviewed study.
Publisher Name
ForLawFirmsOnly Marketing, Inc.
Publisher Logo
Be Sociable, Share!
ForLawFirmsOnly Marketing, Inc. © 1994-2021 All Rights Reserved